Researchers have published the first description of the role of the ZFP36 family of RNA binding proteins in regulatory T cells (Tregs). Tregs are key to maintaining balance in the immune system and ...
COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
The gross proceeds to the Company from the private placement are expected to be approximately $11.1 million, before deducting offering expenses payable by the Company. No broker, placement agent or ...
Loosening chimeric antigen receptor's grip on T-regulatory cells improves function, researchers find
A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...
Lim et al. demonstrate that Treg cells deficient in PD-1 occupy key spatial niches within the TME, with regulatory subsets organized near tumor cells dampening anti-tumor immunity (red and dark blue ...
A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...
COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results